Drugs / Recombinant Variant COVID-19 Vaccine(sf9 cell)
Recombinant Variant COVID-19 Vaccine(sf9 cell)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05911061 Comparator | Dec 2024 → Jun 2025 overdue | COVID-19 | WestVac Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Variant COVID-19 Vaccine(sf9 cell) | “boost with Recombinant Variant COVID-19 Vaccine(sf9 cell)” NCT05911061 ↗ |
| Modality | Vaccine | “Recombinant Variant COVID-19 Vaccine(sf9 cell)” NCT05911061 ↗ |